New developments in the medical management of prostate cancer.
Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.
Kohli
Manish
M
Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Tindall
Donald J
DJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen